Compugen Ltd.
https://www.cgen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Compugen Ltd.
Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Large Molecule
- Other Names / Subsidiaries
-
- Evogene, Compugen USA, Inc, Neviah Genomics Ltd